CLAIMS

1. A compound of formula (I) shown below, or a pharmaceutically acceptable salt thereof:



(I)

wherein:

R_1 is selected from hydrogen or fluoro;

R_2 is selected from hydrogen or methyl; and

R_{4a} and R_{4b} are each independently selected from hydrogen, fluoro, methyl or fluoromethyl (e.g. CF_3, CF_2H, CFH_2), with the proviso that at least one of R_{4a} and R_{4b} is not hydrogen.

2. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R_1 is hydrogen.

3. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R_1 is fluoro.

4. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R_2 is hydrogen.

5. A compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R_2 is methyl.

6. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R_{4a} and R_{4b} are each independently selected from hydrogen, fluoro, methyl, CF_2H, with the proviso that at least one of R_{4a} and R_{4b} is not hydrogen.

7. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein one of the following applies:

a) one of R_{4a} and R_{4b} is methyl and the other is hydrogen;

b) one of R_{4a} and R_{4b} is CF_2H and the other is hydrogen; or

c) R_{4a} and R_{4b} are both fluoro.

8. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein one of the following applies:

a) one of R_{4a} and R_{4b} is methyl and the other is hydrogen; or

b) one of R_{4a} and R_{4b} is CF_2H and the other is hydrogen.

9. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, having a structural formula (II), (IIa), (IIb), (IIc), (IId), (III), (IIIa), (IIIb), (IIIc) or (IIId) below:



(II)



(IIa)



(IIb)



(IIc)



(IId)



(III)



(IIIa)



(IIIb)



(IIIc)



(IIId)

wherein R_1, R_2 and R_{4a} are as defined in any one of the preceding claims.

10. A compound, or a pharmaceutically acceptable salt thereof, selected from any one of the following:
N-[[2-[(3,3-difluoro-8-azabicyclo[3.2.1]octan-8-yl)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide;
N-((5-fluoro-2-(((1R,3r,5S)-3-methyl-8-azabicyclo[3.2.1]octan-8-yl)methyl)-1H-indol-6-yl)methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;
N-((2-(((1R,3s,5S)-3-(difluoromethyl)-8-azabicyclo[3.2.1]octan-8-yl)methyl)-5-fluoro-1H-indol-6-yl)methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;
N-((2-(((1R,3s,5S)-3-(difluoromethyl)-8-azabicyclo[3.2.1]octan-8-yl)methyl)-1H-indol-6-yl)methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;
N-((5-fluoro-2-(((1R,3s,5S)-3-methyl-8-azabicyclo[3.2.1]octan-8-yl)methyl)-1H-indol-6-yl)methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;
N-((2-(((1S*,3R*,5R*)-1,3-dimethyl-8-azabicyclo[3.2.1]octan-8-yl)methyl)-5-fluoro-1H-indol-6-yl)methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; and
N-((2-(((1R*,3S*,5S*)-1,3-dimethyl-8-azabicyclo[3.2.1]octan-8-yl)methyl)-5-fluoro-1H-indol-6-yl)methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide.

11. A pharmaceutical composition comprising a compound according to any one of claim 1 to 10, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

12. A compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 11, for use in therapy.

13. Use of a compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 11, in the manufacture of a medicament for the treatment of a proliferative condition; optionally wherein the proliferative condition is cancer; further optionally wherein the cancer is selected from:

i. leukaemia, e.g. acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL) chronic myeloid leukaemia, chronic lymphocytic leukaemia (CLL)) small lymphocytic lymphoma (SLL) or myelodysplastic syndromes (MDS); or

ii. a cancer of the CNS, e.g. Glioma, Glioblastoma Multiforme (GBM), Astrocytomas, Oligodendrogliomas, Ependyomas, Meningiomas, other brain neoplasms or secondary tumours that have metastasized to the brain.

14. Use of a compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 11, in the manufacture of a medicament for the treatment of:

i. a neurodegenerative disorder, e.g. a tauopathy such as Alzheimer's disease, progressive supranuclear palsy, corticobasal syndrome, frontotemporal dementias, Pick's disease, globular glial tauopathy, argyrophilic grain disease, aging-related tau astrogliopathy, primary age-related tauopathy (PART), Progressive supranuclear palsy, and chronic traumatic encephalopathy; a motor neuron disease (including ALS); a repeat expansion disease (such as Huntington's Disease), dementia (including frontotemporal dementia, vascular dementia and dementia caused by a tauopathy such as Alzheimer's Disease); multiple sclerosis; or Parkinson's Disease; or

ii. a disease related to the inactivation of the X-chromosome, e.g. Addison's disease with cerebral sclerosis; Adrenal hypoplasia; siderius X-linked mental retardation syndrome; Agammaglobulinaemia, Bruton type; Choroidoretinal degeneration; Choroidaemia; Albinism, ocular; Dent's disease 2; fragile X syndrome; Rett/ Epileptic encephalopathy, early infantile, 2 (CDKL5 deficiency disorder); Albinism-deafness syndrome; paroxysmal nocturnal hemoglobinuria; Aldrich syndrome; Alport syndrome; Anaemia, hereditary hypochromic; Anemia, sideroblastic, with ataxia; Fabry disease; Spinal muscular atrophy 2; Cataract, congenital; Charcot-Marie-Tooth, peroneal; Spastic paraplegia; Colour blindness; Diabetes insipidus, nephrogenic; DDX3X syndrome; Dyskeratosis congenita; Ectodermal dysplasia, anhidrotic; Faciogenital dysplasia (Aarskog syndrome); Glucose-6-phosphate dehydrogenase deficiency; Glycogen storage disease type VIII; Gonadal dysgenesis (XY female type); Granul omatous disease (chronic); Haemophilia A; Haemophilia B; Hydrocephalus (aqueduct stenosis); Hypophosphataemic rickets; Lesch-Nyhan syndrome (hypoxanthine-guanine-phosphoribosyl transferase deficiency); Incontinentia pigmenti; Kallmann syndrome; Keratosis follicularis spinulosa; Lowe (oculocerebrorenal) syndrome; Menkes syndrome; Renpenning Syndrome; Mental retardation, with or without fragile site (numerous specific types); Coffin-Lowry syndrome; Microphthalmia with multiple anomalies (Lenz syndrome); Muscular dystrophy (Becker, Duchenne and Emery-Dreifuss types); Myotubular

myopathy; Night blindness, congenital stationary; Norrie's disease (pseudoglioma); Nystagmus, oculomotor or 'jerky'; Orofaciodigital syndrome (type I); Omithine transcarbamylase deficiency (type I hyperammonaemia); Phosphoglycerate kinase deficiency; Phosphoribosylpyrophosphate synthetase deficiency; Retinitis pigmentosa; Retinoschisis; Rett syndrome; Muscular atrophy /Dihydrotestosterone receptor deficiency; Spinal muscular atrophy; Spondyloepiphyseal dysplasia tarda; Thrombocytopenia, hereditary; Thyroxine-binding globulin, absence; or McLeod syndrome; or

iii. an autoimmune disease, a disorder of the CNS, a neurological disease, an inflammatory disease, an infectious disease, type 2 diabetes, a neuropsychiatric behavioural disorder, a depressive disorder or a disease related to the inactivation of the X-chromosome.

15. Use of a compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 11, in the manufacture of a medicament for the inhibition of METTL3 activity.

16. Use of a compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 11, in the manufacture of a medicament for the inhibition of metastasis.

17. A method of inhibiting METTL3 activity *in vitro*, said method comprising contacting a cell with an effective amount of a compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 11.

18. A method of inhibiting metastasis *in vitro*, said method comprising contacting a cell with an effective amount of a compound according to any one claims 1 to 10 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 11.

19. A combination comprising a compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt there, with one or more additional therapeutic agents.